Leukotriene modifiers in the treatment of cardiovascular diseases

Journal of Leukocyte Biology

Volumn 84, Issue 6, 2008, Pages 1374-1378

  Riccioni, Graziano ^a,e   Capra, Valerie ^b   D'Orazio, Nicolantonio ^c   Bucciarelli, Tonino ^c   Bazzano, Lydia A ^d  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d TULANE UNIVERSITY   (United States)

^e NONE   (Italy)

Author keywords

5 LO; ALOX5AP; Antileukotrienes; Atherosclerosis; FLAP; Myocardial infarction; Stroke

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONATE 5 LIPOXYGENASE; CYSTEINYL LEUKOTRIENE RECEPTOR; LEUKOTRIENE; LEUKOTRIENE B1; LEUKOTRIENE B4; PEPTIDOLEUKOTRIENE; UNCLASSIFIED DRUG; ZILEUTON;

CARDIOVASCULAR DISEASE; DRUG EFFECT; HEART DISEASE; HEART MUSCLE ISCHEMIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; SHORT SURVEY;

ANTI-ASTHMATIC AGENTS; CARDIOVASCULAR DISEASES; CYSTEINE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; RECEPTORS, LEUKOTRIENE;

ANIMALIA;

EID: 57149118054     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0808476     Document Type: Short Survey

References (68)

1. Peters-Golden, M., Henderson Jr., W. R. (2007) Leukotrienes. N. Engl. J. Med. 357, 1841-1854.
2. Samuelsson, B., Dahlen, S. E., Lindgren, J. A., Rouzer, C. A., Serhan, C. N. (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237, 1171-1176.
3. Capra, V., Ambrosio, M., Riccioni, G., Rovati, G. E. (2006) Cysteinylleukotriene receptor antagonists: present situation and future opportunities. Curr. Med. Chem. 13, 3213-3226.
4. Coleman, R. A., Eglen, R. M., Jones, R. L. (1995) Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv. Prostaglandin Thromboxane Leukot. Res. 23, 283-285.
5. Riccioni, G., Santilli, F., D'Orazio, N., Sensi, S., Spoltore, R., De Benedictis, M., Guagnano, M. T., Di Ilio, C., Della Vecchia, R. (2002) The role of antileukotrienes in the treatment of asthma. Int. J. Immunopathol. Pharmacol. 15, 171-182.
6. Piper, P. J. (1984) Formation and actions of leukotrienes. Physiol. Rev. 64, 744-761.
7. Funk, C. D. (2005) Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat. Rev. Drug Discov. 4, 664-672.
8. Back, M. (2007) Leukotriene receptors: crucial components in vascular inflammation. ScientificWorldJournal 7, 1422-1439.
9. Funk, C. D., Cyrus, T. (2001) 12/15-Lipoxygenase, oxidative modification of LDL and atherogenesis. Trends Cardiovasc. Med. 11, 116-124.
10. Funk, C. D. (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871-1875.
11. Nicosia, S., Capra, V., Rovati, G. E. (2001) Leukotrienes as mediators of asthma. Pulm. Pharmacol. Ther. 14, 3-19.
12. Ford-Hutchinson, A. W. (1990) Leukotriene B4 in inflammation. Crit. Rev. Immunol. 10, 1-12.
13. Lewis, R. A., Austen, K. F., Sobermann, R. J. (1990) Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 323, 645-655.
14. Gimbrone Jr., M. A., Brock, A. F., Schafer, A. I. (1984) Leukotriene B4 stimulates polymorphonuclear leukocyte adhesion to cultured vascular endothelial cells. J. Clin. Invest. 74, 1552-1555.
15. Capra, V., Thompson, M. D., Sala, A., Cole, D. E., Folco, G., Rovati, G. E. (2007) Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med. Res. Rev. 27, 469-527.
16. Lefer, A. M. (1988) Thromboxane A2 and leukotrienes are eicosanoid mediators of shock and ischemic disorders. Prog. Clin. Biol. Res. 264, 101-114.
17. Brink, C., Dahlen, S. E., Drazen, J., Evans, J. F., Hay, D. W., Nicosia, S., Serhan, C. N., Shimnizu, T., Yokomizo, T. (2003) International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. 55, 195-227.
18. Bandeira-Melo, C., Woods, L. J., Phoofolo, M., Weller, P. F. (2002) Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J. Exp. Med. 196, 841-850.
19. Nielsen, C. K., Campbell, J. I., Ohd, J. F., Morgelin, M., Riesbeck, K., Landberg, G., Sjolander, A. (2005) A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res. 65, 732-742.
20. Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., Wahli, W. (1996) The PPARα-leukotriene B4 pathway to inflammation control. Nature 384, 39-43.
21. Ghazalpour, A., Wang, X., Lusis, A. J., Mehrabian, M. (2006) Complex inheritance of the 5-lipoxygenase locus influencing atherosclerosis in mice. Genetics 173, 943-951.
22. Bäck, M. (2007) Leukotriene receptors: crucial components in vascular inflammation. ScientificWorldJournal 7, 1422-1439.
23. Helgadottir, A., Manolescu, A., Thorleifsson, G., Gretarsdottir, S., Jonsdottir, H., Thorsteinsdottir, U., Samani, N. J., Gudmundsson, G., Grant, S. F., Thorgeirsson, G., et al. (2004) The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet. 36, 233-239.
24. Subbarao, K., Jala, V. R., Mathis, S., Suttles, J., Zacharias, W., Ahamed, J., Ali, H., Tseng, M. T., Haribabu, B. (2004) Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler. Thromb. Vasc. Biol. 24, 369-375.
25. Zhao, L., Moos, M. P., Gräbner, R., Pédrono, F., Fan, J., Kaiser, B., John, N., Schmidt, S., Spanbroek, R., Lötzer, K., Huang, L., Cui, J., Rader, D. J., Evans, J. F., Habenicht, A. J., Funk, C. D. (2004) The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat. Med. 10, 966-973.
26. Spanbroek, R., Grabner, R., Lotzer, K., Hildner, M., Urbach, A., Ruhling, K., Moos, M. P., Kaiser, B., Cohenert, T. U., Wahlers, T., Zieske, A., Plenz, G., Robenek, H., Salbach, P., Kuhn, H., Radmark, O., Samuelsson, B., Habenicht, A. J. (2003) Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. USA 100, 1238-1243.
27. Qiu, H., Gabrielsen, A., Agardh, H. E., Wan, M., Wetterholm, A., Wong, C. H., Hedin, U., Swedenborg, J., Hansson, G. K., Samuelsson, B., Paulsson-Berne, G., Haeggström, J. Z. (2006) Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc. Natl. Acad. Sci. USA 103, 8161-8166.
28. Dwyer, J. H., Allayee, H., Dwyer, K. M., Fan, J., Wu, H., Mar, R., Lusis, A. J., Mehrabian, M. (2004) Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. 350, 29-37.
29. Helgadottir, A., Gretarsdottir, S., St Clair, D., Manolescu, A., Cheung, J., Thorleifsson, G., Pasdar, A., Grant, S. F., Whalley, L. J., Hakonarson, H., Thorsteinsdottir, U., Kong, A., Gulcher, J., Stafansson, K., MacLeod, M. J. (2005) Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am. J. Hum. Genet. 76, 505-509.
30. Lefer, A. M. (1988) Thromboxane A2 and leukotrienes are eicosanoid mediators of shock and ischemic disorders. Prog. Clin. Biol. Res. 264, 101-114.
31. Letts, L. G. (1987) Leukotrienes: role in cardiovascular physiology. Cardiovasc. Clin. 18, 101-113.
32. Hahn, R. A., MacDonald, B. R., Simpson, P. J., Wang, L., Towner, R. D., Ho, P. P., Goodwin, M., Breau, A. P., Suarez, T., Mihelich, E. D. (1991) Characterization of LY233569 on 5-lipoxygenase and reperfusion injury of ischemic myocardium. J. Pharmacol. Exp. Ther. 256, 94-102.
33. Hock, C. E., Beck, L. D., Papa, L. A. (1992) Peptide leukotriene receptor antagonism in myocardial ischemia and reperfusion. Cardiovasc. Res. 26, 1206-1211.
34. Mullane, K., Hatala, M. A., Kraemer, R., Sessa, W., Westlin, W. (1987) Myocardial salvage induced by REV-5901: an inhibitor and antagonist of the leukotrienes. J. Cardiovasc. Pharmacol. 10, 398-406.
35. Hahn, R. A., MacDonald, B. R., Morgan, E., Potts, B. D., Parli, C. J., Rinkema, L. E., Whitesitt, C. A., Marshall, W. S. (1992) Evaluation of LY203647 on cardiovascular leukotriene D4 receptors and myocardial reperfusion injury. J. Pharmacol. Exp. Ther. 260, 979-989.
36. Ito, B. R., Roth, D. M., Engler, R. L. (1990) Thromboxane A2 and peptidoleukotrienes contribute to the myocardial ischemia and contractile dysfunction in response to intracoronary infusion of complement C5a in pigs. Circ. Res. 66, 596-607.
37. Ito, T., Toki, Y., Hieda, Y., Okumura, K., Hashimoto, H., Ogawa, K., Satake, T. (1989) Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart. Jpn. Circ. J. 53, 1115-1121.
38. Amsterdam, E. A., Pan, H. L., Rendig, S. V., Symons, J. D., Fletcher, M. P., Longhurst, J. C. (1993) Limitation of myocardial infarct size in pigs with a dual lipoxygenase-cyclooxygenase blocking agent by inhibition of neutrophil activity without reduction of neutrophil migration. J. Am. Coll. Cardiol. 22, 1738-1744.
39. Kamohara, M., Takasaki, J., Matsumoto, M., Matsumoto, S., Saito, T., Soga, T., Matsushime, H., Furuichi, K. (2001) Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells. Biochem. Biophys. Res. Commun. 287, 1088-1092.
40. Dwyer, J. H., Allayee, H., Dwyer, K. M., Fan, J., Wu, H., Mar, R., Lusis, A. J., Mehrabian, M. (2004) Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. 350, 29-37.
41. Bevan, S. (2008) Genetic variation in members of the leukotriene biosynthesis pathway confer an increase risk of ischemic stroke: a replication study in two independent populations. Stroke 39, 1109-1114.
42. Moskowitz, M. A., Kiwak, K. J., Hekimian, K., Levine, L. (1984) Synthesis of compounds with properties of leukotrienes C4 and D4 in gerbil brains after ischemia and reperfusion. Science 224, 886-889.
43. Minamisawa, H., Terashi, A., Katayama, Y., Kanda, Y., Shimizu, J., Shiratori, T., Inamura, K., Kaseki, H., Yoshino, Y. (1988) Brain eicosanoid levels in spontaneously hypertensive rats after ischemia with reperfusion: leukotriene C4 as a possible cause of cerebral edema. Stroke 19, 372-377.
44. Aktan, S., Aykut, C., Ercan, S. (1991) Leukotriene C4 and prostaglandin E2 activities in the serum and cerebrospinal fluid during acute cerebral ischemia. Prostaglandins Leukot. Essent. Fatty Acids 43, 247-249.
45. Ciceri, P., Rabuffetti, M., Monopoli, M., Nicosia, S. (2001) Production of leukotrienes in a model of focal cerebral ischaemia in the rat. Br. J. Pharmacol. 133, 1323-1329.
46. Bonventre, J. V., Huang, Z., Taheri, M. R., O'Leary, E., Li, E., Moskowitz, M. A., Sapirstein, A. (1997) Reduced fertility and postischemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 390, 622-625.
47. Fang, S. H., Wei, E. Q., Zhou, Y., Wang, M. L., Zhang, W. P., Yu, G. L., Chu, L. S., Chen, Z. (2006) Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats. Neuroscience 140, 969-979.
48. Fang, S. H., Zhou, Y., Chu, L. S., Zhang, W. P., Wang, M. L., Yu, G. L., Peng, F., Wei, E. Q. (2007) Spatio-temporal expression of cysteinyl leukotriene receptor-2 mRNA in rat brain after focal cerebral ischemia. Neurosci. Lett. 412, 78-83.
49. Zhang, Y. J., Zhang, L., Ye, Y. L., Fang, S. H., Zhou, Y., Zhang, W. P., Lu, Y. B., Wei, E. Q. (2006) Cysteinyl leukotriene receptors CysLT1 and CysLT2 are upregulated in acute neuronal injury after focal cerebral ischemia in mice. Acta Pharmacol. Sin. 27, 1553-1560.
50. Huang, X. J., Zhang, W. P., Li, C. T., Shi, W. Z., Fang, S. H., Lu, Y. B., Chen, Z., Wei, E. Q. (2008) Activation of CysLT receptors induces astrocyte proliferation and death after oxygen-glucose deprivation. Glia 56, 27-37.
51. Yu, G. L., Wei, E. Q., Zhang, S. H., Xu, H. M., Chu, L. S., Zhang, W. P., Zhang, Q., Chen, Z., Mei, R. H., Zhao, M. H. (2005) Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. Pharmacology 73, 31-40.
52. Yu, G. L., Wie, E. Q., Wang, M. L., Zhang, W. P., Zhang, S. H., Wenig, J. Q., Chu, L. S., Fang, S. H., Zhou, Y., Chen, Z., Zhang, Q., Zhang, L. H. (2005) Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice. Brain Res. 1053, 116-125.
53. Qian, X. D., Qian, X. D., Wie, E. Q., Zhang, L., Sheng, W. W., Wang, M. L., Zhang, W. P., Chen, Z. (2006) Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, protects mice against brain cold injury. Eur. J. Pharmacol. 549, 35-40.
54. Ciana, P., Fumagalli, M., Trincavelli, M. L., Verderio, C., Rosa, P., Lecca, D., Ferrario, S., Parravicini, C., Capra, V., Gelosa, P., Guerrini, U., Belcredito, S., Cimino, M., Sironi, L., Tremoli, E., Rovati, G. E., Martini, C., Abbracchio, M. P. (2006) The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 25, 4615-4627.
55. Xu, S., McKeever, B. M., Wisniewski, D., Miller, D. K., Spencer, R. H., Chu, L., Ujjainwalla, F., Yamin, T. T., Evans, J. F., Becker, J. W., Ferguson, A. D. (2007) Expression, purification and crystallization of human 5-lipoxygenase-activating protein with leukotriene-biosynthesis inhibitors. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 63, 1054-1057.
56. Ferguson, A. D., McKeever, B. M., Xu, S., Wisniewski, D., Miller, D. K., Yamin, T. T., Spencer, R. H., Chu, L., Ujjainwalla, F., Cunningham, B. R., Evans, J. F., Becker, J. W. (2007) Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 317, 510-512.
57. Peters-Golden, M., Brock, T. G. (2003) 5-Lipoxygenase and FLAP. Prostaglandins Leukot. Essent. Fatty Acids 69, 99-109.
58. Hakonarson, H., Thorvaldsson, S., Helgadottir, A., Gudbjartsson, D., Zink, F., Andresdottir, M., Manolescu, A., Arnar, D. O., Andersen, K., Sigurdsson, A., et al. (2005) Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293, 2245-2256.
59. Helgadottir, A., Manolescu, A., Helgason, A., Thorleifsson, G., Thorsteinsdottir, U., Gudbjartsson, D. F., Gretarsdottir, S., Magnusson, K. P., Gudmundsson, G., Hicks, A., et al. (2006) A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat. Genet. 38, 68-74.
60. Zee, R. Y., Cheng, S., Hegener, H. H., Erlich, H. A., Ridker, P. M. (2006) Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach. Stroke 37, 2007-2011.
61. Maznyczka, A., Mangino, M., Whittaker, A., Braund, P., Palmer, T., Tobin, M., Goodall, A. H., Bradding, P., Samani, N. J. (2007) Leukotriene B4 production in healthy subjects carrying variants of the arachidonate 5-lipoxygenase-activating protein gene associated with a risk of myocardial infarction. Clin. Sci. 112, 411-416.
62. Girelli, D., Martinelli, N., Trabetti, E., Olivieri, O., Cavallari, U., Malerba, G., Busti, F., Friso, S., Pizzolo, F., Pignatti, P. F., Corrocher, R. (2007) ALOX5AP gene variants and risk of coronary artery disease: an angiography-based study. Eur. J. Hum. Genet. 15, 959-966.
63. Koch, W., Hoppmann, P., Mueller, J. C., Schömig, A., Kastrati, A. (2007) No association of polymorphisms in the gene encoding 5-lipoxygenase- activating protein and myocardial infarction in a large central European population. Genet. Med. 9, 123-129.
64. Evans, J. F., Ferguson, A. D., Mosley, R. T., Hutchinson, J. H. (2008) What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol. Sci. 29, 72-78.
65. Hakonarson, H. (2006) Role of FLAP and PDE4D in myocardial infarction and stroke: target discovery and future treatment options. Curr. Treat. Options. Cardiovasc. Med. 8, 183-192.
66. Mocatta, T. J., Pilbrow, A. P., Cameron, V. A., Senthilmohan, R., Frampton, C. M., Richards, A. M., Winterbourn, C. C. (2007) Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J. Am. Coll. Cardiol. 49, 1993-2000.
67. Khan, S. Q., Kelly, D., Quinn, P., Davies, J. E., Ng, L. L. (2007) Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart 93, 826-831.
68. Back, M. (2006) Leukotrienes: potential therapeutic target in cardiovascular diseases. Bull. Acad. Natl. Med. 190, 1511-1518.